Dangers of Pemigatinib

Pemigatinib (Pemigatinib) is an oral targeted therapy for cholangiocarcinoma. While pemetinib has shown some efficacy in treating cholangiocarcinoma, it can also cause some hazards and side effects. Every patient responds differently to the drug, so it's important to have a thorough discussion and evaluation with your doctor before using pemetinib.

The use of pemetinib may cause nausea, vomiting, diarrhea, abdominal pain and other gastrointestinal discomforts. These adverse reactions are usually temporary and can be alleviated by adjusting the dose or giving supportive treatment. Pemetinib may cause hypertension and requires regular monitoring and management. If high blood pressure is found, your doctor may recommend appropriate treatment, such as medication or lifestyle changes. Some patients may develop liver function abnormalities, such as elevated transaminases, after treatment with pemetinib. Regular liver function tests are required, and treatment is adjusted based on the test results.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.